Coya Therapeutics (NASDAQ:COYA – Get Free Report) will likely be posting its quarterly earnings results before the market opens on Tuesday, March 18th. Analysts expect Coya Therapeutics to post earnings of ($0.32) per share for the quarter.
Coya Therapeutics Stock Performance
Shares of COYA opened at $6.49 on Monday. Coya Therapeutics has a 52 week low of $4.75 and a 52 week high of $10.69. The firm has a market cap of $108.43 million, a P/E ratio of -9.98 and a beta of 0.31. The firm’s 50-day simple moving average is $6.28 and its 200 day simple moving average is $6.47.
Analysts Set New Price Targets
A number of brokerages have issued reports on COYA. Chardan Capital restated a “buy” rating and set a $14.00 target price on shares of Coya Therapeutics in a research report on Thursday, February 6th. D. Boral Capital restated a “buy” rating and set a $15.00 target price on shares of Coya Therapeutics in a research report on Monday, March 10th.
Coya Therapeutics Company Profile
Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Further Reading
- Five stocks we like better than Coya Therapeutics
- Investing in the High PE Growth Stocks
- How to Build the Ultimate Everything ETF Portfolio
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Expert Stock Trading Psychology Tips
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
